Oruka Therapeutics, Inc. ORKA Payment-in-kind interest
Payment-in-kind interest at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaidInKindInterest.
The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s payment-in-kind interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s payment-in-kind interest?
- Oruka Therapeutics, Inc. (ORKA) reported payment-in-kind interest of $1.47M in Q4 2024.
- What does payment-in-kind interest mean?
- This metric tracks interest income or expense that is settled through the issuance of additional securities or debt rather than cash payments. It is a non-cash accounting entry that reflects the accrual of interest obligations or earnings on instruments with payment-in-kind features. Monitoring this helps investors understand the true cash-flow impact of debt instruments versus their accounting-based interest accruals.